menu
    • menu
    [{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-s","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Maveropepimut-s","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Immunovaccine Technologies","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunovaccine Technologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovaccine Technologies \/ BioVaxys","highestDevelopmentStatusID":"8","companyTruncated":"Immunovaccine Technologies \/ BioVaxys"}]

    Find Clinical Drug Pipeline Developments & Deals for Maveropepimut-S

    Menu

    Maveropepimut-S

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immunovaccine Technologies

                            Country arrow
                            Compamed
                            Not Confirmed

                            Immunovaccine Technologies

                            Country arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Biovaxys

                            Deal Size : $25.7 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biovaxys Acquires Intellectual Property and Assets Of Former Imv Inc.

                            Details : The acquisition supplements BioVaxys' cancer vaccine portfolio with DPX-Survivac, a cancer vaccine delivering antigenic peptides from survivin, commonly overexpressed in advanced cancers.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : $25.7 million

                            February 12, 2024

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Biovaxys

                            Deal Size : $25.7 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

                            Details : IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 13, 2023

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic,...

                            Details : IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 08, 2023

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

                            Details : DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 20, 2022

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

                            Details : DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 16, 2022

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

                            Details : IMV’s lead candidate, DPX-Survivac (maveropepimut-S, MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting

                            Details : Maveropepimut-S (DPX-Survivac) Generating Cancer-Targeted Killer T Cells combines advantages of DPX platform and cancer antigen survivin, is lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 28, 2022

                            Lead Product(s) : Maveropepimut-S,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR An...

                            Details : Combination of DPX-Survivac (maveropepimut-s) and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy.

                            Brand Name : DPX-Survivac

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed

                            IMV

                            Canada arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maveropepimut-S,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

                            Details : DPX-Survivac, a novel T cell immunotherapy that uses the DPX platform to elicit a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies.

                            Brand Name : DPX-Survivac

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : Maveropepimut-S,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth